In this article, we will be taking a look at the 5 Best Psychedelic Stocks to Buy According to Analysts. If you wish to see the full list, visit 7 Best Psychedelic Stocks to Buy According to Analysts.
wavebreakmedia/Shutterstock.com
5. Silo Pharma, Inc. (NASDAQ:SILO)
Price Target Upside: 76.68%
Silo Pharma, Inc. (NASDAQ:SILO) is one of the best psychedelic stocks on our list.
SILO reported on July 7 that its wholly owned subsidiary, QwikAgents, joined the NVIDIA Developer Program to support the advancement of its artificial intelligence agent integration platform. The program provides QwikAgents with access to NVIDIA’s AI software ecosystem, development tools, technical resources, and optimization support aimed at improving next-generation AI applications. QwikAgents’ platform is designed to automate complex business processes through autonomous AI agents capable of reasoning, executing tasks, and connecting with enterprise systems. The company expects these resources to help accelerate platform development as it expands solutions for organizations seeking scalable AI-driven operations.
Separately, on June 29, Silo Pharma, Inc. (NASDAQ:SILO) announced that it had partnered with Resyca to conduct a robustness evaluation of the microchip-based nasal spray technology being developed for SPC-15, its lead intranasal treatment candidate for post-traumatic stress disorder. The study will assess device reliability during expected use and examine formulation stability over 30 days. SILO believes the nose-to-brain delivery approach may improve drug concentration in the brain while limiting systemic exposure, potentially supporting faster therapeutic effects and enhanced safety. The company is also using regulatory discussions with the FDA to advance development of SPC-15 through the streamlined 505 pathway.
Silo Pharma, Inc. (NASDAQ:SILO) is a developmental-stage biopharmaceutical company combining psychedelic research with traditional therapeutics to develop treatments for conditions such as PTSD, Alzheimer’s disease, multiple sclerosis, and chronic pain.
4. AtaiBeckley Inc. (NASDAQ:ATAI)
Price Target Upside: 169.75%
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best psychedelic stocks on our list.
TheFly reported on July 7 that Canaccord increased its price target on ATAI to $17 from $15 while maintaining a Buy rating on the shares. The firm revised its model following the company’s announcement that it had completed dosing the final participant in the Elumina Phase 2 study evaluating VLS-01, a DMT buccal film, for treatment-resistant depression. Canaccord noted that ATAI remains on track to report topline results in the fourth quarter of 2026.
On July 6, AtaiBeckley Inc. (NASDAQ:ATAI) announced the completion of patient dosing in its Phase 2b Elumina clinical trial evaluating VLS-01 in adults with treatment-resistant depression. The multi-center, double-blind, placebo-controlled study enrolled 156 participants, with topline results expected in the fourth quarter of 2026. The company plans to progress VLS-01 into Phase 3 development for major depressive disorder, while generalized anxiety disorder remains a potential future indication. ATAI stated that VLS-01, alongside BPL-003, which is currently in Phase 3 development for treatment-resistant depression with Breakthrough Therapy Designation, could support a broader approach to treating mood and anxiety disorders.
AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company formed through the merger of Atai Life Sciences and Beckley Psytech, focused on developing fast-acting, long-lasting psychedelic-based treatments for difficult-to-treat mental health disorders.
3. Vistagen Therapeutics, Inc. (NASDAQ:VTGN)
Price Target Upside: 322.12%
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is one of the best psychedelic stocks on our list.
TheFly reported on June 30 that VTGN announced topline findings from the PALISADE-4 Phase 3 trial evaluating intranasal fasedienol for the acute treatment of social anxiety disorder. The study did not meet its primary endpoint, with fasedienol failing to demonstrate a statistically meaningful improvement compared with placebo based on the change from baseline in SUDS scores. The trial also showed no treatment advantage over placebo across secondary endpoints. However, fasedienol maintained a favorable safety and tolerability profile, consistent with observations from earlier placebo-controlled clinical studies.
Separately, earlier on June 15, Vistagen Therapeutics, Inc. (NASDAQ:VTGN) reported its financial results for the fiscal year ended March 31, 2026, along with a corporate update. Research and development expenses increased to $55.0 million from $39.4 million in the prior fiscal year, primarily due to activities supporting the PALISADE Program for fasedienol, manufacturing efforts, and development of the company’s pherine candidates. General and administrative expenses rose to $18.4 million compared with $17.1 million a year earlier. The company recorded a net loss of $69.7 million for the fiscal year, compared with $51.4 million in the previous period. As of March 31, 2026, VTGN reported $45.4 million in cash, cash equivalents, and marketable securities, which it expects to support operations into 2027.
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is a clinical-stage neuroscience company developing rapid-onset intranasal therapies for psychiatric disorders. It is often categorized among psychedelic stocks due to its focus on mental health innovation, though its proprietary therapies are not classic psychedelics.
2. Cybin D/B/A Helus Pharma (NASDAQ:HELP)
Price Target Upside: 430.68%
Cybin D/B/A Helus Pharma (NASDAQ:HELP) is one of the best psychedelic stocks on our list.
TheFly reported on July 1 that Canaccord analyst Sumant Kulkarni lowered the price target on HELP to $42 from $45 while maintaining a Buy rating on the shares. The firm highlighted Helus Pharma’s lead candidate, HLP003, a deuterated psilocin analog currently being evaluated in a Phase 3 program for adjunctive treatment of major depressive disorder (MDD). Canaccord expects significant potential upside from upcoming Phase 3 APPROACH trial results for HLP003, which are anticipated in the fourth quarter of 2026.
In other news, earlier on June 24, Cybin D/B/A Helus Pharma (NASDAQ:HELP) announced the pricing of an underwritten public offering involving 10,309,280 common shares. The shares were offered for $4.85 each, generating approximately $50 million in gross proceeds for the company. The offering was expected to close on June 25. Cantor and Barclays served as joint bookrunning managers for the transaction, while Bloom Burton Securities and Lucid Capital Markets acted as lead managers. The capital raise is intended to support HELP’s ongoing operations and advancement of its development programs.
Cybin D/B/A Helus Pharma (NASDAQ:HELP) is a clinical-stage neuropsychiatry company developing psychedelic-based therapies and novel serotonergic agonists for mental health conditions such as major depressive disorder and generalized anxiety disorder.
1. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)
Price Target Upside: 1,029.81%
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is one of the best psychedelic stocks on our list.
TheFly reported on June 25 that NRXP issued a statement responding to claims made by Kadima Neuropsychiatry Institute regarding the failed acquisition of Kadima by HOPE Therapeutics, a majority-owned subsidiary of NRx. The company stated that it had initiated arbitration proceedings over Kadima’s failure to satisfy key transaction requirements, including asset ownership verification and business condition obligations. NRXP said management believes pursuing the acquisition would not benefit patients or shareholders and emphasized that HOPE’s strategy remains focused on developing advanced treatments for depression, PTSD, and other serious conditions. The company also highlighted ongoing initiatives involving neuronavigated TMS technology, neuroplastic medicines, and partnerships supporting its evolving personalized medicine approach.
In other news, on June 22, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced that the FDA approved an Intermediate Population Expanded Access Protocol for NRX-101, a fixed-dose combination of D-cycloserine and lurasidone, to support its use alongside accelerated Transcranial Magnetic Stimulation (TMS). The program is intended to provide access to NRX-101 through FDA-authorized compassionate use pathways for patients unable to participate in the company’s pivotal trial. NRXP stated that the initiative supports broader evaluation of the therapy’s potential to improve TMS outcomes. The company also highlighted its upcoming SPARC-TMS pivotal trial, which will assess the combination’s ability to address depression remission and suicidality in patients with treatment-resistant depression.
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company developing CNS therapies for severe mental health conditions, including suicidal depression, bipolar depression, and PTSD.
While we acknowledge the potential of NRXP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NRXP and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: Billionaire Cliff Asness’ Top 10 Healthcare Stock Picks and 10 Best Stocks to Buy Now for Good Returns.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
